Adélie Gothland

Dr. Adélie Gothland

Sorbonne Université, Hôpital Pitié-Salpêtrière (AP-HP)
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2018 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
PEPierre Evenou
Pierre Evenou
JRJulien Rossignol
Julien Rossignol
GPGaëlle Pembouong
Gaëlle Pembouong
AGAdélie Gothland
Adélie Gothland
DCDmitri Colesnic
Dmitri Colesnic
MSMatthieu Sollogoub
Matthieu Sollogoub


13 April 2023 in Journal of Infection
Verified
Journal Article
Closed access
ETElisa Teyssou
Elisa Teyssou
SMStéphane Marot
Stéphane Marot
AGAdélie Gothland
Adélie Gothland
IMIsabelle Malet
Isabelle Malet
KZKaren Zafilaza
Karen Zafilaza
VCVincent Calvez
Vincent Calvez

21 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
AGAdélie Gothland
Adélie Gothland
VLValentin Leducq
Valentin Leducq
Philippe GrangePhilippe Grange
Philippe Grange
FOFaye Ousmane
Faye Ousmane
LRLAURIANNE BEAUVAIS REMIGEREAU
LAURIANNE BEAUVAIS REMIGEREAU
VCVincent Calvez
Vincent Calvez
Human Herpesvirus 8 (HHV-8) is associated with three main severe orphan malignancies, Kaposi’s sarcoma (KS), multicentric Castleman’s disease (MCD), and primary effusion lymphoma (PEL), which present few therapeutic options. We identified the antimalarial primaquine diphosphate (PQ) as a promising therapeutic candidate for HHV-8-associated PEL and KS. Indeed, PQ strongly reduced cell viability through caspase-dependent apoptosis, specifically in HHV-8-infected PEL cells. Reactive oxygen species (ROS)- and endoplasmic reticulum (ER) stress-mediated apoptosis signaling pathways were found to be part of the in vitro cytotoxic effect of PQ. Moreover, PQ treatment had a clinically positive effect in a nonobese diabetic (NOD)/SCID xenograft PEL mouse model, showing a reduction in tumor growth and an improvement in survival. Finally, an exploratory proof-of-concept clinical trial in four patients harboring severe KS was conducted, with the main objectives to assess the efficacy, the safety, and the tolerability of PQ, and which demonstrated a positive efficacy on Kaposi’s sarcoma-related lesions and lymphedema.